Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions

Disclosure This study was sponsored by Allergan, Inc., Irvine, CA, USA. JHC, JWK, and VDP are employees of Allergan, Inc. GFS has acted as a clinical expert consultant to Allergan, Inc. for this project, but has not received any compensation. GFS does receive ongoing research support from Allergan, Inc. on other projects, as well as from Tissue Banks International. BL is an employee of Principled Strategies, Inc.